Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New...
| Website | http://www.affymax.com |
| Ticker | AFFY |
| Revenue | $750000 |
| Employees | 30 (6 on RocketReach) |
| Founded | 2001 |
| Address | 630 5th Ave Ste 2260, New York, New York 10111, US |
| Phone | +1 650-812-8700 |
| Fax | (650) 424-0832 |
| Industry | Biotechnology, Business Services General, Biopharma, Pharmaceuticals, Business Services, Drug Discovery, Health Care, Science and Engineering |
| Keywords | Biotechnology, Drug Development, Pharmaceutical, Drug Discovery, Therapeutics, Biopharma, Biotechnology Research, Pharmaceutical Research, Novel Therapeutics, Life Sciences, Clinical Trials, Prescription Drugs, Treatment, Medical Research, Disease, Healthcare, Health |
| Competitors | Johnson & Johnson, Roche, Novartis, Sanofi, AstraZeneca, Amgen, Gilead Sciences, Biogen, Lilly India, Keryx Biopharmaceuticals +35 more (view full list) |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies |
Looking for a particular Affymax employee's phone or email?
The Affymax annual revenue was $750000 in 2026.
Daniel Cooper is the Executive Director, Drug Safety and Pharmacovigilance of Affymax.
6 people are employed at Affymax.
Affymax is based in New York, New York.
The NAICS codes for Affymax are [32, 32541, 3254, 325].
The SIC codes for Affymax are [28, 283].